Werewolf Therapeutics financials
$0.9100−2.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $1.9M | $19.9M | $16.4M | $0.00 |
| Gross profit | $0.00 | $1.9M | $19.9M | $16.4M | $0.00 |
| Gross margin | — | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$60.7M | -$73.6M | -$40.5M | -$56.1M | -$50.1M |
| Net income | -$60.8M | -$70.5M | -$37.4M | -$53.8M | -$201.9M |
| Net margin | — | −3740.8% | −187.4% | −328.1% | — |
| Diluted EPS | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 |
| EBITDA | -$59.0M | -$71.8M | -$38.7M | -$53.5M | -$49.9M |
| Operating cash flow | -$60.3M | -$56.2M | -$32.6M | -$40.6M | -$42.9M |
| Free cash flow | -$60.3M | -$56.4M | -$33.4M | -$44.2M | -$43.4M |
| Diluted shares | 46.8M | 43.9M | 35.6M | 28.9M | 18.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $57.0M | $111.0M | $134.3M | $129.3M | $157.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $28.2M | $26.1M | $39.3M | $0.00 | $0.00 |
| Total assets | $69.4M | $126.9M | $174.8M | $160.2M | $179.3M |
| Total liabilities | $44.6M | $53.5M | $63.5M | $37.9M | $26.5M |
| Shareholders' equity | $24.8M | $73.4M | $111.4M | $122.3M | $152.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology